| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/24/2001 | EP1147108A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof |
| 10/24/2001 | EP1147107A1 Novel angiogenesis inhibitors |
| 10/24/2001 | EP1147106A1 Process for the preparation of alkyl mercapto methyl ergoline derivatives |
| 10/24/2001 | EP1147105A1 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatement of vascular diseases |
| 10/24/2001 | EP1147104A1 Aromatic heterocyclic compounds as antiinflammatory agents |
| 10/24/2001 | EP1147103A1 Phenantrhridine-n-oxides with pde-iv inhibiting activity |
| 10/24/2001 | EP1147102A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 10/24/2001 | EP1147101A1 Reverse hydroxamate inhibitors of matrix metalloproteinases |
| 10/24/2001 | EP1147095A1 2, 3, 4, 5-tetrahydro-1h-[1, 4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors |
| 10/24/2001 | EP1147094A1 Non-peptide glp-1 agonists |
| 10/24/2001 | EP1147093A1 Substituted bicyclic derivatives useful as anticancer agents |
| 10/24/2001 | EP1147092A1 Substituted imidazoles, their preparation and use |
| 10/24/2001 | EP1147091A2 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 10/24/2001 | EP1147089A1 Phenylphenanthridines with pde-iv inhibiting activity |
| 10/24/2001 | EP1147088A1 6-arylphenanthridines with pde-iv inhibiting activity |
| 10/24/2001 | EP1147087A1 Phenanthridine-n-oxides with pde-iv inhibiting activity |
| 10/24/2001 | EP1147086A1 Compositions for the treatment of skin diseases |
| 10/24/2001 | EP1147085A1 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors |
| 10/24/2001 | EP1147084A1 Phenylsulphonyl derivatives as 5-ht receptor ligands |
| 10/24/2001 | EP1147083A1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
| 10/24/2001 | EP1147081A1 Carotenoid degradation products having an anti-tumoral effect |
| 10/24/2001 | EP1147080A1 Alkynyl containing hydroxamic acid compounds as tace inhibitors |
| 10/24/2001 | EP1147079A2 Beta-phenylalanine derivatives as integrin antagonists |
| 10/24/2001 | EP1147078A1 Acetylenic (beta)-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors |
| 10/24/2001 | EP1146959A1 Method and apparatus for liposome production |
| 10/24/2001 | EP1146913A2 Conjugates of colony stimulating factors for targeting and imaging infection and inflammation |
| 10/24/2001 | EP1146909A1 Method of treating cancer by restoration of pp32 function |
| 10/24/2001 | EP1146908A1 Formulations comprising antisense nucleotides to connexins |
| 10/24/2001 | EP1146907A2 Use of cationic lipids to generate anti-tumor immunity |
| 10/24/2001 | EP1146905A1 Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| 10/24/2001 | EP1146901A1 Potentiation of anti-cd38-immunotoxin cytotoxicity |
| 10/24/2001 | EP1146898A1 Vaccine-mediated treatment of neurological disorders |
| 10/24/2001 | EP1146895A2 Methods for increasing circulating platelets for collection and cryopreservation using thrombopoietin compositions |
| 10/24/2001 | EP1146892A2 Baff, inhibitors thereof and their use in the modulation of the b-cell response |
| 10/24/2001 | EP1146889A2 Identification of specific differentially expressed mycobacterial antigens |
| 10/24/2001 | EP1146886A1 Soya extract containing lipids, process for its production, and pharmaceutical and cosmetic composition |
| 10/24/2001 | EP1146884A1 Novel polymer formulations containing perfluorinated compounds for the engineering of cells and tissues for transplantation that improves cell metabolism and survival, and methods for making same |
| 10/24/2001 | EP1146883A1 Modulation of immune response by ribavirin |
| 10/24/2001 | EP1146882A2 Combination of zidovudine (azt) with nucleoside analogs for treatment of feline immunodeficiency virus |
| 10/24/2001 | EP1146881A2 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |
| 10/24/2001 | EP1146880A2 Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections |
| 10/24/2001 | EP1146879A1 Methods and compositions for prevention and treatment of restenosis with non-steroidal anti-inflammatory drugs |
| 10/24/2001 | EP1146877A1 Method of using (2-imidazolin-2-ylamino) quinoxalines in treating neural injury |
| 10/24/2001 | EP1146876A2 Compositions having improved stability |
| 10/24/2001 | EP1146875A1 Myt1 kinase inhibitors |
| 10/24/2001 | EP1146874A1 Vitronectin receptor antagonist |
| 10/24/2001 | EP1146873A1 Anti-androgens and methods for treating disease |
| 10/24/2001 | EP1146872A1 Use of angiotensin ii receptor antagonists for treating acute myocardial infarction |
| 10/24/2001 | EP1146871A1 Antidepressant heterocyclic compounds |
| 10/24/2001 | EP1146870A1 Antioxidant compositions and methods for companion animals |
| 10/24/2001 | EP1146869A2 Inhibition of stat3 signal transduction for human cancer therapy |
| 10/24/2001 | EP1146868A1 Anti-inflammatory agents |
| 10/24/2001 | EP1146867A1 Antibacterial hydroxamic acid derivatives |
| 10/24/2001 | EP1146866A1 A method for treating patients with acne by administering a cyclic gmp pde inhibitor |
| 10/24/2001 | EP1146865A1 Pharmaceutical composition comprising a combination of dextro- and laevo- isomers of sotalol |
| 10/24/2001 | EP1146864A1 Ph independent extended release pharmaceutical formulation |
| 10/24/2001 | EP1146863A1 Lyophilisates with improved reconstitutibility |
| 10/24/2001 | EP1146862A1 Pharmaceutical compositions |
| 10/24/2001 | EP1146859A1 Method of preparing particles for agglomeration |
| 10/24/2001 | EP1146851A1 Galenic formulation containing biotin |
| 10/24/2001 | EP1146847A1 Cosmetic composition comprising at least a film-forming polymer and at least a regulating agent |
| 10/24/2001 | EP1146845A2 Compressed lecithin preparations |
| 10/24/2001 | EP1146792A1 Chewing gum with dental health benefits employing calcium lactate |
| 10/24/2001 | EP1146790A1 Compounds and methods |
| 10/24/2001 | EP1146789A1 Treating cancers associated with overexpression of her-2/neu |
| 10/24/2001 | EP1146788A1 Amide derivatives for antiangiogenic and/or antitumorigenic use |
| 10/24/2001 | EP1146787A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| 10/24/2001 | EP1045843A4 Inhibitors of farnesyl-protein transferase |
| 10/24/2001 | EP1035824A4 A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| 10/24/2001 | EP0975618B1 a new process for the preparation of 3-N,N-dicycobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide |
| 10/24/2001 | EP0934593A4 Electrically conductive adhesive hydrogels |
| 10/24/2001 | EP0921791B1 Composition comprising mupirocin and chlorhexidine |
| 10/24/2001 | EP0906295B1 Dibenzo-oxazepine and -dioxepine derivatives and their use as anti-tumor agents |
| 10/24/2001 | EP0904064B1 Oral pharmaceutical compositions containing sex hormones |
| 10/24/2001 | EP0892796B1 Isatin derivatives as acetylcholinesterase inhibitors and analgesics |
| 10/24/2001 | EP0869955B1 N-acyl-2-substituted-4-(benzimidazolyl- or imidazopyridinyl-substituted residues)-piperidines as tachykinin antagonists |
| 10/24/2001 | EP0863751B1 Improved method for preventing crystal formation in a dispersion of a liquid in a matrix |
| 10/24/2001 | EP0858341B1 Combination therapy for advanced cancer comprising temozolomide and cisplatin |
| 10/24/2001 | EP0856002B1 Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings |
| 10/24/2001 | EP0854721B1 Endothelin receptor antagonists |
| 10/24/2001 | EP0848704B1 Form iii crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
| 10/24/2001 | EP0847242B1 Sugar-free dragee-like products |
| 10/24/2001 | EP0840733B1 A triazolylmethyl-indole ethylamine bisulfate salt |
| 10/24/2001 | EP0840601B1 Thip for treating sleep disorders |
| 10/24/2001 | EP0835246B1 Aromatic compounds and pharmaceutical compositions containing them |
| 10/24/2001 | EP0820433B1 O-malonyltyrosyl compounds, o-malonyltyrosyl compound-containing peptides, and uses thereof |
| 10/24/2001 | EP0818994B1 Method of making a pressure sensitive skin adhesive sheet material |
| 10/24/2001 | EP0809698B1 NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF TUMOR GENE Int6 |
| 10/24/2001 | EP0809657B1 Process for producing chitosan-glucan complexes, compounds producible therefrom and their use |
| 10/24/2001 | EP0775142B1 Substituted o6 -benzylguanines |
| 10/24/2001 | EP0755393B1 Novel crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4- 3-(1-methylethylamino)-2-pyridinyl]piperazine |
| 10/24/2001 | EP0751763B1 Substances, combinations of active substances and compositions against skin ageing |
| 10/24/2001 | EP0731801B1 Substituted aminoalkylaminopyridines |
| 10/24/2001 | EP0723435B1 Once-a-day metoprolol oral dosage form |
| 10/24/2001 | EP0711163B1 Use of benzydamine in the treatment of pathological conditions caused by tnf |
| 10/24/2001 | EP0705099B1 Use of modafinil for the treatment of sleep apnoea and ventilation problems of central origin |
| 10/24/2001 | EP0662833B1 Aqueous composition |
| 10/24/2001 | EP0660713B1 Use of angiotensin ii antagonists in the treatment of left ventricular hypertrophy |
| 10/24/2001 | EP0648212B1 Benzoxazole and benzothiazole derivatives as pharmaceutical |
| 10/24/2001 | EP0641206B1 Use of cotinine to alleviate tobacco withdrawal syndrome |